Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy

Inflammatory Bowel Diseases

Volumn 19, Issue 13, 2013, Pages 2763-2767

  Miehlke, Stephan ^a   Hansen, Jesper B ^b   Madisch, Ahmed ^c   Schwarz, Franca ^d   Kuhlisch, Eberhard ^e   Morgner, Andrea ^f   Teglbjaerg, Peter S ^b   Vieth, Michael ^g   Aust, Daniela ^d   Bonderup, Ole K ^h  

^a Center for Digestive Diseases   (Germany)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c Hospital Siloah   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f Flughafen Hamburg GmbH   (Germany)

^g INSTITUTE OF PATHOLOGY   (Germany)

^h SILKEBORG REGIONAL HOSPITAL   (Denmark)

Author keywords

Budesonide; Collagenous colitis; Lymphocytic colitis; Microscopic colitis

Indexed keywords

BUDESONIDE;

ADULT; ARTICLE; COLLAGENOUS COLITIS; DIARRHEA; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RELAPSE; RISK FACTOR; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, COLLAGENOUS; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84890559187     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000438135.88681.98     Document Type: Article

References (20)

1. Bjørnbak C, Engel PJH, Nielsen PL, et al. Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups. Aliment Pharmacol Ther. 2011;34:1225-1234.
2. Olesen M, Eriksson S, Bohr J, et al. Microscopic colitis: a common diarrhoeal disease. An epidemiological study in Orebro, Sweden, 1993-1998. Gut. 2004;53:346-350.
3. Pardi DS, Loftus EV Jr, Smyrk TC, et al. The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut. 2007;56:504-508.
4. Stewart M, Andrews CN, Urbanskià S, et al. The association of coeliac disease and microscopic colitis: a large population-based study. Aliment Pharmacol Ther. 2011;33:1340-1349.
5. Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis. 2005;20:312-316.
6. Hjortswang C, Tysk C, Bohr J, et al. Defining clinical criteria for clinical remission and disease activity in collagenous colitis. Inflamm Bowel Dis. 2009;15:1875-1881.
7. Hjortswang H, Tysk C, Bohr J, et al. Health related quality of life is impaired in active collagenous colitis. Dig Liver Dis. 2011;43:102-109.
8. Baert F, Schmit A, D'Haens G, et al. Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-up. Gastroenterology. 2002;122:20-25.
9. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis -A randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002;123:978-984.
10. Bonderup OK, Hansen JB, Birket-Smith L, et al. Budesonide treatment of collagenous colitis: a randomised, double-blind, placebo-controlled trial with morpho-metric analysis. Gut. 2003;52:248-251.
11. Miehlke S, Madisch A, Voss C, et al. Long-term follow-up of collagenous colitis after duction of clinical remission with budesonide. Aliment Pharmacol Ther. 2005;22:1115-1119.
12. Miehlke S, Madisch A, Bethke B, et al. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebocontrolled trial. Gastroenterology. 2008;135:1510-1516.
13. Bonderup OK, Hansen JB, Teglbjaerg PS, et al. Long-term budesonide treatment of collagenous colitis -A randomised, double-blind, placebocontrolled trial. Gut. 2009;58:68-72.
14. Münch A, Bohr J, Benoni C, et al. Budesonide induces clinical remission and improves quality of life in active collagenous colitis: results from the open-label induction phase of BUC-63/COC. J Crohn Colitis. 2013; 7:S238.
15. Vigren L, Sjöberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis? Scand J Gastroenterol. 2011;46:1334-1339.
16. Yen EF, Pokhrel B, Du H, et al. Current and past cigarette smoking significantly increase risk for microscopic colitis. Inflamm Bowel Dis. 2012;18:1835-1841.
17. Fernández-Bañares F, de Sousa MR, Salas A, et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013;19:411-417.
18. Fernández-Bañares F, de Sousa MR, Salas A, et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis. 2012;19:1470-1476.
19. Miehlke S, Madisch A, Karimi D, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology. 2009;136:2092-2100.
20. Pardi DS, Loftus EV Jr, Tremaine WJ, et al. A randomized double-blind, placebo controlled trial of budesonide for the treatment of active lymphocytic colitis. Gastroenterology. 2009;136(suppl 1):T1193.